Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2013 financial results before the market opens on Wednesday, August 7, 2013, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.
Interested parties may participate in the conference call by dialing 1-877-941-8631 (US) or 1-480-629-9644 (international), 5-10 minutes prior to the start of the call. A replay of the conference call will be available approximately 2 hours after the call’s conclusion through 12:00 p.m. ET (Eastern Time) on August 21, 2013 by dialing 1-800-406-7325 (US) or 1-303-590-3030 (international), and entering the access code 4632564. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares Web site at www.antarespharma.com.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP™, a combination product for the delivery of methotrexate using Medi-Jet™ technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and psoriasis, as well as VIBEX™ QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX™ disposable Medi-Jet™, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH), VIBEX™ epinephrine and several other products. Antares Pharma’s partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet™ and pen injector systems. The Company’s corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.
Antares Pharma, Inc.
Vice President, Corporate Affairs
|Antares Pharma to Host Third Quarter 2013 Operating and Financial Results Conference Call (2013/10/31)|
|U.S. Energy Corp. Schedules Second Quarter 2013 Highlights and Financial Results Conference Call/Webcast ()|
|Alexandria Real Estate Equities, Inc. To Hold Its Third Quarter 2013 Operating And Financial Results Conference Call And Web Cast On October 29, 2013 (2013/9/30)|
|Antares Pharma Reports Second Quarter 2013 Operating and Financial Results ()|
|TRC to Host First-Quarter Fiscal Year 2014 Financial Results Conference Call on November 6 (2013/11/1)|
|U.S. Energy Corp. Schedules Third Quarter 2013 Highlights and Financial Results Conference Call/Webcast (2013/11/6)|
|Rex Energy Reports Second Quarter 2013 Operational and Financial Results ()|
|Antares Pharma Reports Third Quarter 2013 Operating and Financial Results (2013/11/6)|
|American Software, Inc. Invites You to Join Its Second Quarter Fiscal Year 2014 Preliminary Results Conference Call on the Web (2013/11/8)|
|NetApp Hosts Second Quarter Fiscal Year 2014 Financial Results Webcast (2013/10/31)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.